If a patient has a history of gastrectomy and is experiencing macrocytic anaemia, it is likely that they are suffering from B12 deficiency.

Vitamin B12 is essential for the development of red blood cells and the maintenance of the nervous system. It is absorbed through the binding of intrinsic factor, which is secreted by parietal cells in the stomach, and actively absorbed in the terminal ileum. A deficiency in vitamin B12 can be caused by pernicious anaemia, post gastrectomy, a vegan or poor diet, disorders or surgery of the terminal ileum, Crohn’s disease, or metformin use.

Symptoms of vitamin B12 deficiency include macrocytic anaemia, a sore tongue and mouth, neurological symptoms, and neuropsychiatric symptoms such as mood disturbances. The dorsal column is usually affected first, leading to joint position and vibration issues before distal paraesthesia.

Management of vitamin B12 deficiency involves administering 1 mg of IM hydroxocobalamin three times a week for two weeks, followed by once every three months if there is no neurological involvement. If a patient is also deficient in folic acid, it is important to treat the B12 deficiency first to avoid subacute combined degeneration of the cord.

If Howell-Jolly bodies are present in the peripheral smear of a sickle cell anemia patient, it indicates that they have undergone autosplenectomy. Sickle cell disease can lead to various complications, including vaso-occlusive crisis, parvovirus B19 infections, splenic sequestration, and eventually, autosplenectomy. However, based on the absence of symptoms and other factors, vaso-occlusive crisis, parvovirus B19 infection, and splenic sequestration are unlikely causes in this case.

Pathological Red Cell Forms in Blood Films

Blood films are used to examine the morphology of red blood cells and identify any abnormalities. Pathological red cell forms are associated with various conditions and can provide important diagnostic information. Some of the common pathological red cell forms include target cells, tear-drop poikilocytes, spherocytes, basophilic stippling, Howell-Jolly bodies, Heinz bodies, schistocytes, pencil poikilocytes, burr cells (echinocytes), and acanthocytes.

Target cells are seen in conditions such as sickle-cell/thalassaemia, iron-deficiency anaemia, hyposplenism, and liver disease. Tear-drop poikilocytes are associated with myelofibrosis, while spherocytes are seen in hereditary spherocytosis and autoimmune hemolytic anaemia. Basophilic stippling is a characteristic feature of lead poisoning, thalassaemia, sideroblastic anaemia, and myelodysplasia. Howell-Jolly bodies are seen in hyposplenism, while Heinz bodies are associated with G6PD deficiency and alpha-thalassaemia. Schistocytes or ‘helmet cells’ are seen in conditions such as intravascular haemolysis, mechanical heart valve, and disseminated intravascular coagulation. Pencil poikilocytes are seen in iron deficiency anaemia, while burr cells (echinocytes) are associated with uraemia and pyruvate kinase deficiency. Acanthocytes are seen in abetalipoproteinemia.

In addition to these red cell forms, hypersegmented neutrophils are seen in megaloblastic anaemia. Identifying these pathological red cell forms in blood films can aid in the diagnosis and management of various conditions.

Antiphospholipid syndrome is a condition where the body’s immune system produces antibodies that cause blood clots and pregnancy-related complications. The diagnosis requires one clinical event and two positive blood tests spaced at least 3 months apart. The antibodies associated with this syndrome are lupus anticoagulant, anti-cardiolipin, and anti-β2-glycoprotein. Antiphospholipid syndrome can be primary or secondary, with the latter occurring in conjunction with other autoimmune diseases. In severe cases, the condition can lead to organ failure, known as catastrophic antiphospholipid syndrome. Treatment typically involves anticoagulant medication such as heparin, while warfarin is avoided during pregnancy due to its teratogenic effects.

Hypercoagulability is a condition where the blood has an increased tendency to clot. There are several types of thrombophilia, each with their own unique features. Antithrombin deficiency is a rare genetic defect that increases the risk of thrombotic events by 10 times. Heparin may not be effective in treating this condition as it works via antithrombin. Protein C and S deficiency, which accounts for up to 5% of thrombotic episodes, occurs when there is a lack of natural anticoagulants that are produced by the liver. Factor V Leiden is the most common genetic defect accounting for deep vein thrombosis (DVT) and may account for up to 20% or more of thrombotic episodes. Antiphospholipid syndrome is a multi-organ disease that can involve pregnancy and cause both arterial and venous thrombosis. It is characterized by either Lupus anticoagulant or Anti cardiolipin antibodies, and requires anticoagulation with an INR between 3 and 4.

In summary, hypercoagulability is a condition where the blood has an increased tendency to clot. There are several types of thrombophilia, each with their own unique features. Antithrombin deficiency, protein C and S deficiency, factor V Leiden, and antiphospholipid syndrome are some of the most common types of thrombophilia. It is important to identify and treat these conditions to prevent thrombotic events.

Unless proven otherwise, the presence of neurological symptoms along with abdominal pain may indicate either acute intermittent porphyria or lead poisoning.

Understanding Acute Intermittent Porphyria

Acute intermittent porphyria (AIP) is a rare genetic disorder that affects the biosynthesis of haem due to a defect in the porphobilinogen deaminase enzyme. This results in the accumulation of delta aminolaevulinic acid and porphobilinogen, leading to a range of symptoms. AIP typically presents in individuals aged 20-40 years, with females being more commonly affected.

The condition is characterized by a combination of abdominal, neurological, and psychiatric symptoms. Abdominal symptoms include pain and vomiting, while neurological symptoms may manifest as motor neuropathy. Psychiatric symptoms may include depression. Hypertension and tachycardia are also common.

Diagnosis of AIP involves a range of tests, including urine analysis, assay of red cells for porphobilinogen deaminase, and measurement of serum levels of delta aminolaevulinic acid and porphobilinogen. A classic sign of AIP is the deep red color of urine on standing.

Management of AIP involves avoiding triggers and treating acute attacks with IV haematin/haem arginate. In cases where these treatments are not immediately available, IV glucose may be used. With proper management, individuals with AIP can lead healthy and fulfilling lives.

The initial impact of vitamin B12 deficiency is typically on the dorsal column, causing impairment in joint position and vibration perception before the onset of distal paraesthesia.

Vitamin B12 is essential for the development of red blood cells and the maintenance of the nervous system. It is absorbed through the binding of intrinsic factor, which is secreted by parietal cells in the stomach, and actively absorbed in the terminal ileum. A deficiency in vitamin B12 can be caused by pernicious anaemia, post gastrectomy, a vegan or poor diet, disorders or surgery of the terminal ileum, Crohn’s disease, or metformin use.

Symptoms of vitamin B12 deficiency include macrocytic anaemia, a sore tongue and mouth, neurological symptoms, and neuropsychiatric symptoms such as mood disturbances. The dorsal column is usually affected first, leading to joint position and vibration issues before distal paraesthesia.

Management of vitamin B12 deficiency involves administering 1 mg of IM hydroxocobalamin three times a week for two weeks, followed by once every three months if there is no neurological involvement. If a patient is also deficient in folic acid, it is important to treat the B12 deficiency first to avoid subacute combined degeneration of the cord.

The presence of necrosis in a tumour may indicate that it has become too large for its blood supply, suggesting a high grade tumour. However, when grading breast cancer using the Bloom-Richardson model, nuclear features such as mitoses, coarse chromatin, and pleomorphism are given more weight. The formation of tubular structures is a key indicator of the level of differentiation, with well differentiated tumours showing the presence of tubules.

Tumour Grading and Differentiation

Tumours can be classified based on their degree of differentiation, mitotic activity, and other characteristics. The grading system ranges from grade 1, which is the most differentiated, to grade 3 or 4, which is the least. The evaluation is subjective, but generally, high-grade tumours indicate a poor prognosis or rapid growth.

Glandular epithelium tumours tend to form acinar structures with a central lumen. Well-differentiated tumours exhibit excellent acinar formation, while poorly differentiated tumours appear as clumps of cells around a desmoplastic stroma. Some tumours produce mucous without acinar formation, and these are referred to as mucinous adenocarcinomas. Squamous cell tumours produce structures resembling epithelial cell components, and well-differentiated tumours may also produce keratin, depending on the tissue of origin.

Cytarabine is a medication used in chemotherapy to treat acute myeloid leukaemia (AML). It works by interfering with DNA synthesis during the S-phase of the cell cycle and inhibiting DNA polymerase.

Allopurinol is a medication that inhibits xanthine oxidase, which prevents the production of uric acid. It is commonly used to treat gout, but can also be used to prevent hyperuricaemia in high-grade lymphoma and leukaemia before chemotherapy treatment.

Methotrexate works by inhibiting dihydrofolate reductase and thymidylate synthesis. It is used to treat rheumatoid arthritis and various types of cancer.

Ondansetron is an anti-emetic medication that is used to prevent nausea during chemotherapy treatment. It works by selectively blocking serotonin receptors (5-HT3) in the chemoreceptor trigger zone (CTZ) of the medulla.

Cytotoxic agents are drugs that are used to kill cancer cells. There are several types of cytotoxic agents, each with their own mechanism of action and potential adverse effects. Alkylating agents, such as cyclophosphamide, work by causing cross-linking in DNA. However, they can also cause haemorrhagic cystitis, myelosuppression, and transitional cell carcinoma. Cytotoxic antibiotics, like bleomycin and anthracyclines, degrade preformed DNA and stabilize DNA-topoisomerase II complex, respectively. However, they can also cause lung fibrosis and cardiomyopathy. Antimetabolites, such as methotrexate and fluorouracil, inhibit dihydrofolate reductase and thymidylate synthesis, respectively. However, they can also cause myelosuppression, mucositis, and liver or lung fibrosis. Drugs that act on microtubules, like vincristine and docetaxel, inhibit the formation of microtubules and prevent microtubule depolymerisation & disassembly, respectively. However, they can also cause peripheral neuropathy, myelosuppression, and paralytic ileus. Topoisomerase inhibitors, like irinotecan, inhibit topoisomerase I, which prevents relaxation of supercoiled DNA. However, they can also cause myelosuppression. Other cytotoxic drugs, such as cisplatin and hydroxyurea, cause cross-linking in DNA and inhibit ribonucleotide reductase, respectively. However, they can also cause ototoxicity, peripheral neuropathy, hypomagnesaemia, and myelosuppression.

Guidelines for Red Blood Cell Transfusion

In 2015, NICE released guidelines for the use of blood products, specifically red blood cells. These guidelines recommend different transfusion thresholds for patients with and without acute coronary syndrome (ACS). For patients without ACS, the transfusion threshold is 70 g/L, while for those with ACS, it is 80 g/L. The target hemoglobin level after transfusion is 70-90 g/L for patients without ACS and 80-100 g/L for those with ACS. It is important to note that these thresholds should not be used for patients with ongoing major hemorrhage or those who require regular blood transfusions for chronic anemia.

When administering red blood cells, it is crucial to store them at 4°C prior to infusion. In non-urgent scenarios, a unit of RBC is typically transfused over a period of 90-120 minutes. By following these guidelines, healthcare professionals can ensure safe and effective transfusions for their patients.

If DNA cannot be repaired, it triggers cellular apoptosis instead of necrosis.

Genetic Conditions and Their Association with Surgical Diseases

Li-Fraumeni Syndrome is an autosomal dominant genetic condition caused by mutations in the p53 tumour suppressor gene. Individuals with this syndrome have a high incidence of malignancies, particularly sarcomas and leukaemias. The diagnosis is made when an individual develops sarcoma under the age of 45 or when a first-degree relative is diagnosed with any cancer below the age of 45 and another family member develops malignancy under the age of 45 or sarcoma at any age.

BRCA 1 and 2 are genetic conditions carried on chromosome 17 and chromosome 13, respectively. These conditions are linked to developing breast cancer with a 60% risk and an associated risk of developing ovarian cancer with a 55% risk for BRCA 1 and 25% risk for BRCA 2. BRCA2 mutation is also associated with prostate cancer in men.

Lynch Syndrome is another autosomal dominant genetic condition that causes individuals to develop colonic cancer and endometrial cancer at a young age. 80% of affected individuals will get colonic and/or endometrial cancer. High-risk individuals may be identified using the Amsterdam criteria, which include three or more family members with a confirmed diagnosis of colorectal cancer, two successive affected generations, and one or more colon cancers diagnosed under the age of 50 years.

Gardners syndrome is an autosomal dominant familial colorectal polyposis that causes multiple colonic polyps. Extra colonic diseases include skull osteoma, thyroid cancer, and epidermoid cysts. Desmoid tumours are seen in 15% of individuals with this syndrome. Due to colonic polyps, most patients will undergo colectomy to reduce the risk of colorectal cancer. It is now considered a variant of familial adenomatous polyposis coli.

Overall, these genetic conditions have a significant association with surgical diseases, and early identification and management can help reduce the risk of malignancies and other associated conditions.

Angiosarcoma of the liver is a tumor that is not commonly found. However, it has been associated with exposure to vinyl chloride, as seen in this instance. While current factories have taken measures to reduce exposure to this substance, this was not always the case.

Occupational cancers are responsible for 5.3% of cancer deaths, with men being more affected than women. The most common types of cancer in men include mesothelioma, bladder cancer, non-melanoma skin cancer, lung cancer, and sino-nasal cancer. Occupations that have a high risk of developing tumors include those in the construction industry, coal tar and pitch workers, miners, metalworkers, asbestos workers, and those in the rubber industry. Shift work has also been linked to breast cancer in women.

The latency period between exposure to carcinogens and the development of cancer is typically 15 years for solid tumors and 20 years for leukemia. Many occupational cancers are rare, such as sino-nasal cancer, which is linked to wood dust exposure and is not strongly associated with smoking. Another rare occupational tumor is angiosarcoma of the liver, which is linked to working with vinyl chloride. In non-occupational contexts, these tumors are extremely rare.

Factor VIII is produced in the endothelial cells located in the liver, which makes it less susceptible to the impact of liver dysfunction.

Abnormal coagulation can be caused by various factors such as heparin, warfarin, disseminated intravascular coagulation (DIC), and liver disease. Heparin prevents the activation of factors 2, 9, 10, and 11, while warfarin affects the synthesis of factors 2, 7, 9, and 10. DIC affects factors 1, 2, 5, 8, and 11, and liver disease affects factors 1, 2, 5, 7, 9, 10, and 11.

When interpreting blood clotting test results, different disorders can be identified based on the levels of activated partial thromboplastin time (APTT), prothrombin time (PT), and bleeding time. Haemophilia is characterized by increased APTT levels, normal PT levels, and normal bleeding time. On the other hand, von Willebrand’s disease is characterized by increased APTT levels, normal PT levels, and increased bleeding time. Lastly, vitamin K deficiency is characterized by increased APTT and PT levels, and normal bleeding time. Proper interpretation of these results is crucial in diagnosing and treating coagulation disorders.

Apixaban is a medication that directly inhibits factor Xa, which is responsible for the conversion of prothrombin to thrombin in the coagulation cascade. It is used as prophylaxis against embolic events in patients with atrial fibrillation, who are at increased risk due to blood pooling in the atria and potential clot formation. Unlike heparin, which activates antithrombin III to reduce blood clotting, apixaban works independently of antithrombin III. It also does not directly inhibit thrombin, which is the mechanism of action of dabigatran. Antiplatelets, such as aspirin and clopidogrel, work to decrease platelet activation and aggregation, but are not recommended for reducing the risks of embolic events in AF. Apixaban also does not inhibit vitamin K, which is the mechanism of action of warfarin.

Direct oral anticoagulants (DOACs) are medications used to prevent stroke in non-valvular atrial fibrillation (AF), as well as for the prevention and treatment of venous thromboembolism (VTE). To be prescribed DOACs for stroke prevention, patients must have certain risk factors, such as a prior stroke or transient ischaemic attack, age 75 or older, hypertension, diabetes mellitus, or heart failure. There are four DOACs available, each with a different mechanism of action and method of excretion. Dabigatran is a direct thrombin inhibitor, while rivaroxaban, apixaban, and edoxaban are direct factor Xa inhibitors. The majority of DOACs are excreted either through the kidneys or the liver, with the exception of apixaban and edoxaban, which are excreted through the feces. Reversal agents are available for dabigatran and rivaroxaban, but not for apixaban or edoxaban.

Dilutional anemia can occur as a result of saline administration, which does not improve oxygen transport or coagulopathy.

When the blood group of a patient is unknown, O rhesus negative blood may be administered as it is considered the universal donor. However, to conserve O negative blood stocks, transfusion guidelines now recommend giving male patients O positive blood in such situations, as Rhesus status is only relevant in pregnancy.

It is crucial to ensure that the correct blood product is prescribed and administered to the right patient, as transfusion reactions can be severe and fatal.

Blood Products and Cell Saver Devices

Blood products are essential in various medical procedures, especially in cases where patients require transfusions due to anaemia or bleeding. Packed red cells, platelet-rich plasma, platelet concentrate, fresh frozen plasma, and cryoprecipitate are some of the commonly used whole blood fractions. Fresh frozen plasma is usually administered to patients with clotting deficiencies, while cryoprecipitate is a rich source of Factor VIII and fibrinogen. Cross-matching is necessary for all blood products, and cell saver devices are used to collect and re-infuse a patient’s own blood lost during surgery.

Cell saver devices come in two types, those that wash the blood cells before re-infusion and those that do not. The former is more expensive and complicated to operate but reduces the risk of re-infusing contaminated blood. The latter avoids the use of donor blood and may be acceptable to Jehovah’s witnesses. However, it is contraindicated in malignant diseases due to the risk of facilitating disease dissemination.

In some surgical patients, the use of warfarin can pose specific problems and may require the use of specialised blood products. Warfarin reversal can be achieved through the administration of vitamin K, fresh frozen plasma, or human prothrombin complex. Fresh frozen plasma is used less commonly now as a first-line warfarin reversal, and human prothrombin complex is preferred due to its rapid action. However, it should be given with vitamin K as factor 6 has a short half-life.

The spleen is responsible for breaking down most of the red blood cells. This is achieved through the action of macrophages that identify and eliminate old red blood cells. It is worth noting that in a healthy individual, the liver, kidneys, and blood vessels do not participate in the breakdown of red blood cells. Additionally, while the bone marrow plays a crucial role in producing blood cells, it is not involved in the destruction of red blood cells.

Understanding Haemolytic Anaemias by Site

Haemolytic anaemias can be classified by the site of haemolysis, either intravascular or extravascular. In intravascular haemolysis, free haemoglobin is released and binds to haptoglobin. As haptoglobin becomes saturated, haemoglobin binds to albumin forming methaemalbumin, which can be detected by Schumm’s test. Free haemoglobin is then excreted in the urine as haemoglobinuria and haemosiderinuria. Causes of intravascular haemolysis include mismatched blood transfusion, red cell fragmentation due to heart valves, TTP, DIC, HUS, paroxysmal nocturnal haemoglobinuria, and cold autoimmune haemolytic anaemia.

On the other hand, extravascular haemolysis occurs when red blood cells are destroyed by macrophages in the spleen or liver. This type of haemolysis is commonly seen in haemoglobinopathies such as sickle cell anaemia and thalassaemia, hereditary spherocytosis, haemolytic disease of the newborn, and warm autoimmune haemolytic anaemia.

It is important to understand the site of haemolysis in order to properly diagnose and treat haemolytic anaemias. While both intravascular and extravascular haemolysis can lead to anaemia, the underlying causes and treatment approaches may differ.

The lumbar lymph nodes, also referred to as the para-aortic lymph nodes, receive drainage from the ovary.

Lymphatic drainage is the process by which lymphatic vessels carry lymph, a clear fluid containing white blood cells, away from tissues and organs and towards lymph nodes. The lymphatic vessels that drain the skin and follow venous drainage are called superficial lymphatic vessels, while those that drain internal organs and structures follow the arteries and are called deep lymphatic vessels. These vessels eventually lead to lymph nodes, which filter and remove harmful substances from the lymph before it is returned to the bloodstream.

The lymphatic system is divided into two main ducts: the right lymphatic duct and the thoracic duct. The right lymphatic duct drains the right side of the head and right arm, while the thoracic duct drains everything else. Both ducts eventually drain into the venous system.

Different areas of the body have specific primary lymph node drainage sites. For example, the superficial inguinal lymph nodes drain the anal canal below the pectinate line, perineum, skin of the thigh, penis, scrotum, and vagina. The deep inguinal lymph nodes drain the glans penis, while the para-aortic lymph nodes drain the testes, ovaries, kidney, and adrenal gland. The axillary lymph nodes drain the lateral breast and upper limb, while the internal iliac lymph nodes drain the anal canal above the pectinate line, lower part of the rectum, and pelvic structures including the cervix and inferior part of the uterus. The superior mesenteric lymph nodes drain the duodenum and jejunum, while the inferior mesenteric lymph nodes drain the descending colon, sigmoid colon, and upper part of the rectum. Finally, the coeliac lymph nodes drain the stomach.

An immune checkpoint inhibitor, Ipilimumab is a type of drug that is used as an alternative to cytotoxic chemotherapy. However, it is currently only prescribed for solid tumours and is administered through intravenous injection.

Understanding Immune Checkpoint Inhibitors

Immune checkpoint inhibitors are a type of immunotherapy that is becoming increasingly popular in the treatment of certain types of cancer. Unlike traditional therapies such as chemotherapy, these targeted treatments work by harnessing the body’s natural anti-cancer immune response. They boost the immune system’s ability to attack and destroy cancer cells, rather than directly affecting their growth and proliferation.

T-cells are an essential part of our immune system that helps destroy cancer cells. However, some cancer cells produce high levels of proteins that turn T-cells off. Checkpoint inhibitors block this process and reactivate and increase the body’s T-cell population, enhancing the immune system’s ability to recognize and fight cancer cells.

There are different types of immune checkpoint inhibitors, including Ipilimumab, Nivolumab, Pembrolizumab, Atezolizumab, Avelumab, and Durvalumab. These drugs block specific proteins found on T-cells and cancer cells, such as CTLA-4, PD-1, and PD-L1. They are administered by injection or intravenous infusion and can be given as a single-agent treatment or combined with chemotherapy or each other.

However, the mechanism of action of these drugs can result in side effects termed ‘Immune-related adverse events’ that are inflammatory and autoimmune in nature. This is because all immune cells are boosted by these drugs, not just the ones that target cancer. The overactive T-cells can produce side effects such as dry, itchy skin and rashes, nausea and vomiting, decreased appetite, diarrhea, tiredness and fatigue, shortness of breath, and a dry cough. Management of such side effects reflects the inflammatory nature, often involving corticosteroids. It is important to monitor liver, kidney, and thyroid function as these drugs can affect these organs.

In conclusion, the early success of immune checkpoint inhibitors in solid tumors has generated tremendous interest in further developing and exploring these strategies across the oncology disease spectrum. Ongoing testing in clinical trials creates new hope for patients affected by other types of disease.

ESR and its association with diseases

Erythrocyte sedimentation rate (ESR) is a laboratory test that measures the rate at which red blood cells settle in a tube over a period of time. Elevated ESR levels are often associated with inflammatory diseases such as rheumatoid arthritis, systemic lupus erythematosus, and polymyalgia rheumatica. In these conditions, the body’s immune system is activated, leading to inflammation and tissue damage. Malignancies such as myeloma can also cause an increase in ESR levels, particularly in females and with increasing age.

On the other hand, low ESR levels are seen in conditions such as polycythaemia, where there is an excess of red blood cells in the body. It is important to note that ESR is not a specific diagnostic test and must be interpreted in conjunction with other clinical findings. Multiple myeloma, a type of plasma cell neoplasm, is the most common haematological malignancy and can lead to a range of symptoms such as hypercalcaemia, renal failure, anaemia, and bone pain. While it is not curable, advances in treatment have significantly improved the median survival of patients. the association between ESR and various diseases can aid in the diagnosis and management of these conditions.

Methotrexate treatment can lead to megaloblastic macrocytic anemia due to a deficiency of folate.

The patient’s low hemoglobin and high MCV indicate macrocytic anemia, which can be caused by various factors such as alcohol abuse, hypothyroidism, aplastic anemia, and megaloblastic anemia due to a deficiency of vitamin B12 and/or folate. In this case, the patient has a history of rheumatoid arthritis and takes methotrexate weekly, which inhibits dihydrofolate reductase and causes a deficiency of folate. Therefore, folate deficiency is the most probable cause of the patient’s anemia.

Alcohol excess is an incorrect option as it usually requires larger quantities of alcohol to cause macrocytic anemia.

Anaemia of chronic disease is an incorrect option as it typically results in normocytic or microcytic anemia, not macrocytic anemia.

Iron deficiency anemia is an incorrect option as it causes microcytic anemia, and the MCV value would be lower than expected.

Understanding Macrocytic Anaemia

Macrocytic anaemia is a type of anaemia that can be classified into two categories: megaloblastic and normoblastic. Megaloblastic anaemia is caused by a deficiency in vitamin B12 or folate, which leads to the production of abnormally large red blood cells in the bone marrow. This type of anaemia can also be caused by certain medications, alcohol, liver disease, hypothyroidism, pregnancy, and myelodysplasia.

On the other hand, normoblastic anaemia is caused by an increase in the number of immature red blood cells, known as reticulocytes, in the bone marrow. This can occur as a result of certain medications, such as methotrexate, or in response to other underlying medical conditions.

It is important to identify the underlying cause of macrocytic anaemia in order to provide appropriate treatment. This may involve addressing any nutritional deficiencies, managing underlying medical conditions, or adjusting medications. With proper management, most cases of macrocytic anaemia can be successfully treated.

Sickle cell disease can be definitively diagnosed through haemoglobin electrophoresis. In the case of a patient experiencing an acute haemolytic episode due to sickle cell disease, normocytic anaemia with a high reticulocyte count and the presence of Howell jolly bodies indicate hyposplenism. A peripheral smear showing sickle cells is also highly indicative of sickle cell disease, which is an autosomal recessive condition that may be present in other family members.

The osmotic fragility test is used to diagnose hereditary spherocytosis by exposing red blood cells to varying osmolarity and observing their fragility. Plasma folate deficiency can lead to macrocytic anaemia, but this is not the case in sickle cell disease. Flow cytometry is not useful in diagnosing sickle cell disease, but it can be used to classify leukemias and diagnose paroxysmal nocturnal haemoglobinuria.

If an autoimmune cause is suspected, a Coombs test can be performed to confirm the pathogenesis, as in the case of haemolytic disease of the newborn. Haemoglobin electrophoresis is one of the definitive tests for diagnosing sickle cell trait and disease, as it shows a decrease in normal haemoglobin A and the presence of haemoglobin S. Genetic analysis can also confirm the diagnosis.

Understanding Sickle-Cell Anaemia

Sickle-cell anaemia is a genetic disorder that occurs when an abnormal haemoglobin chain, known as HbS, is synthesized due to an autosomal recessive condition. This condition is more common in people of African descent, as the heterozygous condition offers some protection against malaria. In the UK, around 10% of Afro-Caribbean individuals are carriers of HbS. Symptoms in homozygotes typically do not develop until 4-6 months when the abnormal HbSS molecules take over from fetal haemoglobin.

The pathophysiology of sickle-cell anaemia involves the substitution of the polar amino acid glutamate with the non-polar valine in each of the two beta chains (codon 6) of haemoglobin. This substitution decreases the water solubility of deoxy-Hb, causing HbS molecules to polymerize and sickle in the deoxygenated state. HbAS patients sickle at p02 2.5 – 4 kPa, while HbSS patients sickle at p02 5 – 6 kPa. Sickle cells are fragile and can cause haemolysis, block small blood vessels, and lead to infarction.

To diagnose sickle-cell anaemia, haemoglobin electrophoresis is the definitive test. It is essential to understand the pathophysiology and symptoms of sickle-cell anaemia to provide appropriate care and management for affected individuals.

Metastatic ovarian cancer is often first detected in the para-aortic lymph nodes, as this is where the ovaries drain. The fundus of the uterus drains to the deep inguinal nodes through lymphatics that follow the round ligament. The inferior mesenteric nodes receive drainage from the upper part of the rectum, sigmoid colon, and descending colon. The body of the uterus drains to the iliac nodes through lymphatics that follow the broad ligament, while parts of the cervix may drain to the presacral nodes via lymphatics that follow the uterosacral fold.

Lymphatic Drainage of Female Reproductive Organs

The lymphatic drainage of the female reproductive organs is a complex system that involves multiple nodal stations. The ovaries drain to the para-aortic lymphatics via the gonadal vessels. The uterine fundus has a lymphatic drainage that runs with the ovarian vessels and may thus drain to the para-aortic nodes. Some drainage may also pass along the round ligament to the inguinal nodes. The body of the uterus drains through lymphatics contained within the broad ligament to the iliac lymph nodes. The cervix drains into three potential nodal stations; laterally through the broad ligament to the external iliac nodes, along the lymphatics of the uterosacral fold to the presacral nodes and posterolaterally along lymphatics lying alongside the uterine vessels to the internal iliac nodes. Understanding the lymphatic drainage of the female reproductive organs is important for the diagnosis and treatment of gynecological cancers.

The thymus receives its arterial supply from either the internal mammary artery or the pericardiophrenic arteries.

During coronary artery bypass surgery, the internal thoracic artery, also referred to as the internal mammary artery, is utilized.

The Thymus Gland: Development, Structure, and Function

The thymus gland is an encapsulated organ that develops from the third and fourth pharyngeal pouches. It descends to the anterior superior mediastinum and is subdivided into lobules, each consisting of a cortex and a medulla. The cortex is made up of tightly packed lymphocytes, while the medulla is mostly composed of epithelial cells. Hassall’s corpuscles, which are concentrically arranged medullary epithelial cells that may surround a keratinized center, are also present.

The inferior parathyroid glands, which also develop from the third pharyngeal pouch, may be located with the thymus gland. The thymus gland’s arterial supply comes from the internal mammary artery or pericardiophrenic arteries, while its venous drainage is to the left brachiocephalic vein. The thymus gland plays a crucial role in the development and maturation of T-cells, which are essential for the immune system’s proper functioning.

The medulla of the thymus contains concentric rings of epithelial cells known as Hassall’s corpuscles.

The Thymus Gland: Development, Structure, and Function

The thymus gland is an encapsulated organ that develops from the third and fourth pharyngeal pouches. It descends to the anterior superior mediastinum and is subdivided into lobules, each consisting of a cortex and a medulla. The cortex is made up of tightly packed lymphocytes, while the medulla is mostly composed of epithelial cells. Hassall’s corpuscles, which are concentrically arranged medullary epithelial cells that may surround a keratinized center, are also present.

The inferior parathyroid glands, which also develop from the third pharyngeal pouch, may be located with the thymus gland. The thymus gland’s arterial supply comes from the internal mammary artery or pericardiophrenic arteries, while its venous drainage is to the left brachiocephalic vein. The thymus gland plays a crucial role in the development and maturation of T-cells, which are essential for the immune system’s proper functioning.

The lymphatic system of the breast is responsible for draining excess fluid and waste products. Lymph from the upper outer quadrant of the breast drains to the axillary lymph nodes, while lymph from the inner quadrants drains to the parasternal lymph nodes. Additionally, some lymph from the lower quadrants drains to the inferior phrenic lymph nodes.

Lymphatic drainage is the process by which lymphatic vessels carry lymph, a clear fluid containing white blood cells, away from tissues and organs and towards lymph nodes. The lymphatic vessels that drain the skin and follow venous drainage are called superficial lymphatic vessels, while those that drain internal organs and structures follow the arteries and are called deep lymphatic vessels. These vessels eventually lead to lymph nodes, which filter and remove harmful substances from the lymph before it is returned to the bloodstream.

The lymphatic system is divided into two main ducts: the right lymphatic duct and the thoracic duct. The right lymphatic duct drains the right side of the head and right arm, while the thoracic duct drains everything else. Both ducts eventually drain into the venous system.

Different areas of the body have specific primary lymph node drainage sites. For example, the superficial inguinal lymph nodes drain the anal canal below the pectinate line, perineum, skin of the thigh, penis, scrotum, and vagina. The deep inguinal lymph nodes drain the glans penis, while the para-aortic lymph nodes drain the testes, ovaries, kidney, and adrenal gland. The axillary lymph nodes drain the lateral breast and upper limb, while the internal iliac lymph nodes drain the anal canal above the pectinate line, lower part of the rectum, and pelvic structures including the cervix and inferior part of the uterus. The superior mesenteric lymph nodes drain the duodenum and jejunum, while the inferior mesenteric lymph nodes drain the descending colon, sigmoid colon, and upper part of the rectum. Finally, the coeliac lymph nodes drain the stomach.

Paroxysmal nocturnal hemoglobinuria (PNH) is a chronic form of intrinsic hemolytic anemia that can present with symptoms such as hematuria, anemia, and venous thrombosis. The classic triad of PNH includes hemolytic anemia, pancytopenia, and venous thrombosis. The gold standard test for PNH is flow cytometry for CD59 and CD55, which shows a deficiency of these proteins on red and white blood cells.

A deficiency of C3 is a complement deficiency disorder that increases the risk of recurrent bacterial infections. While a deficiency of CD59 or CD55 may be present in this patient, PNH patients typically have a deficiency of both proteins. Terminal complement deficiency, indicated by a deficiency of complements forming the membrane attack membrane, confers a high risk of infection with Neisseria organisms. Eculizumab, a humanized monoclonal antibody, is approved for the treatment of PNH and works by inhibiting the terminal complement cascade.

Understanding Paroxysmal Nocturnal Haemoglobinuria

Paroxysmal nocturnal haemoglobinuria (PNH) is a condition that causes the breakdown of haematological cells, mainly intravascular haemolysis. It is believed to be caused by a lack of glycoprotein glycosyl-phosphatidylinositol (GPI), which acts as an anchor that attaches surface proteins to the cell membrane. This leads to the improper binding of complement-regulating surface proteins, such as decay-accelerating factor (DAF), to the cell membrane. As a result, patients with PNH are more prone to venous thrombosis.

PNH can affect red blood cells, white blood cells, platelets, or stem cells, leading to pancytopenia. Patients may also experience haemoglobinuria, which is characterized by dark-coloured urine in the morning. Thrombosis, such as Budd-Chiari syndrome, is also a common feature of PNH. In some cases, patients may develop aplastic anaemia.

To diagnose PNH, flow cytometry of blood is used to detect low levels of CD59 and CD55. This has replaced Ham’s test as the gold standard investigation for PNH. Ham’s test involves acid-induced haemolysis, which normal red cells would not undergo.

Management of PNH involves blood product replacement, anticoagulation, and stem cell transplantation. Eculizumab, a monoclonal antibody directed against terminal protein C5, is currently being trialled and is showing promise in reducing intravascular haemolysis. Understanding PNH is crucial in managing this condition and improving patient outcomes.

DIC, also known as consumptive coagulopathy, is a condition where the coagulation cascade is overactivated, leading to unchecked bleeding. This is due to the depletion of clotting mechanisms. Normally, clot formation and breakdown are balanced, with thrombin playing a key role in both processes. In DIC, patients may have prolonged coagulation times, thrombocytopenia, high levels of fibrin degradation products, elevated D-dimer levels, and microangiopathic pathology on peripheral smears. The excess fibrin strands in the intravascular circulation cause mechanical damage to red blood cells, resulting in schistocyte formation, thrombocytopenia, and consumption of clotting factors. Bite cells are abnormally shaped red blood cells with semicircular portions removed from the cell margin, seen in G6PD deficiency. Dacrocytes are teardrop-shaped cells seen in myelofibrosis and marrow disorders, while elliptocytes are red cells varying in shape from elongated to oval, seen in various disorders.

Disseminated Intravascular Coagulation: A Condition of Simultaneous Coagulation and Haemorrhage

Disseminated intravascular coagulation (DIC) is a medical condition characterized by simultaneous coagulation and haemorrhage. It is caused by the initial formation of thrombi that consume clotting factors and platelets, ultimately leading to bleeding. DIC can be caused by various factors such as infection, malignancy, trauma, liver disease, and obstetric complications.

Clinically, bleeding is usually the dominant feature of DIC, accompanied by bruising, ischaemia, and organ failure. Blood tests can reveal prolonged clotting times, thrombocytopenia, decreased fibrinogen, and increased fibrinogen degradation products. The treatment of DIC involves addressing the underlying cause and providing supportive management.

In summary, DIC is a serious medical condition that requires prompt diagnosis and management. It is important to identify the underlying cause and provide appropriate treatment to prevent further complications. With proper care and management, patients with DIC can recover and regain their health.

Lymphomas and their Staging

Malignancies that arise from lymphocytes can spread to different lymph node groups due to their ability to retain adhesion and signalling receptors. Lymphomas can present at various sites, including bone marrow, gut, and spleen, as normal trafficking of lymphoid cells occurs through these places. Interestingly, higher-grade lymphomas are easier to cure than lower grade lymphomas, despite initially being associated with a higher mortality rate. On the other hand, low-grade lymphomas may not require immediate treatment, but the disease progresses over time, leading to a poorer prognosis.

To diagnose lymphoma, a biopsy of the affected area, such as a lymph node or bone marrow, is necessary. The Ann Arbor staging system is used to stage lymphomas, with Stage I indicating disease in a single lymph node group and Stage IV indicating extra-nodal involvement other than the spleen. The addition of a ‘B’ signifies the presence of ‘B’ symptoms, which are associated with a poorer prognosis for each disease stage.

From the examination findings, it is evident that the disease is present on both sides of the diaphragm, indicating at least Stage III lymphoma. the staging of lymphomas is crucial in determining the appropriate treatment plan and predicting the patient’s prognosis.

The primary cause of hypercalcemia in multiple myeloma is increased osteoclast activity in response to cytokines released by the myeloma cells. This neoplasm of bone marrow plasma cells is most commonly seen in males aged 60-70 years old, which fits the demographic of the patient in this scenario. It is important to investigate patients presenting with hypercalcemia for an underlying diagnosis of multiple myeloma. Decreased osteoblast function, elevated PTH-rP levels, and impaired renal function are less contributing factors to hypercalcemia in myeloma compared to increased osteoclastic activity. Although impaired renal function is commonly seen in multiple myeloma, it is not stated whether this patient has decreased renal function.

Understanding Multiple Myeloma: Features and Investigations

Multiple myeloma is a type of cancer that affects the plasma cells in the bone marrow. It is most commonly found in patients aged 60-70 years. The disease is characterized by a range of symptoms, which can be remembered using the mnemonic CRABBI. These include hypercalcemia, renal damage, anemia, bleeding, bone lesions, and increased susceptibility to infection. Other features of multiple myeloma include amyloidosis, carpal tunnel syndrome, neuropathy, and hyperviscosity.

To diagnose multiple myeloma, a range of investigations are required. Blood tests can reveal anemia, renal failure, and hypercalcemia. Protein electrophoresis can detect raised levels of monoclonal IgA/IgG proteins in the serum, while bone marrow aspiration can confirm the diagnosis if the number of plasma cells is significantly raised. Imaging studies, such as whole-body MRI or X-rays, can be used to detect osteolytic lesions.

The diagnostic criteria for multiple myeloma require one major and one minor criteria or three minor criteria in an individual who has signs or symptoms of the disease. Major criteria include the presence of plasmacytoma, 30% plasma cells in a bone marrow sample, or elevated levels of M protein in the blood or urine. Minor criteria include 10% to 30% plasma cells in a bone marrow sample, minor elevations in the level of M protein in the blood or urine, osteolytic lesions, or low levels of antibodies in the blood. Understanding the features and investigations of multiple myeloma is crucial for early detection and effective treatment.

Hb SC is a less severe variant of sickle cell disease that can be detected early through screening of children in the UK. This condition is characterized by the presence of both the sickle mutation and the HbC mutation, which results in a lysine substitution for glutamic acid on position 6 of the beta chain. While HbSC shares similarities with sickle cell disease, its symptoms are less frequent and severe. The severity of the disease can vary depending on the specific genotype, with HbAA being normal, HbAS being asymptomatic, HbSC/Sβ+ being moderately affected, and HbSS/Sβ0 being severely affected due to the absence of normal haemoglobin.

Understanding Sickle-Cell Anaemia

Sickle-cell anaemia is a genetic disorder that occurs when an abnormal haemoglobin chain, known as HbS, is synthesized due to an autosomal recessive condition. This condition is more common in people of African descent, as the heterozygous condition offers some protection against malaria. In the UK, around 10% of Afro-Caribbean individuals are carriers of HbS. Symptoms in homozygotes typically do not develop until 4-6 months when the abnormal HbSS molecules take over from fetal haemoglobin.

The pathophysiology of sickle-cell anaemia involves the substitution of the polar amino acid glutamate with the non-polar valine in each of the two beta chains (codon 6) of haemoglobin. This substitution decreases the water solubility of deoxy-Hb, causing HbS molecules to polymerize and sickle in the deoxygenated state. HbAS patients sickle at p02 2.5 – 4 kPa, while HbSS patients sickle at p02 5 – 6 kPa. Sickle cells are fragile and can cause haemolysis, block small blood vessels, and lead to infarction.

To diagnose sickle-cell anaemia, haemoglobin electrophoresis is the definitive test. It is essential to understand the pathophysiology and symptoms of sickle-cell anaemia to provide appropriate care and management for affected individuals.

The translocation of chromosomes is associated with various types of lymphoma and leukaemia. For example, the t(14;18) translocation causes follicular lymphoma by increasing BCL-2 transcription. Similarly, the t(8;14) translocation causes Burkitt lymphoma, while the t(9;22) translocation leads to the Philadelphia chromosome and chronic myeloid leukaemia. Mantle cell lymphoma is associated with the t(11;14) translocation. These translocations can help diagnose and classify these haematological malignancies.

Genetics of Haematological Malignancies

Haematological malignancies are cancers that affect the blood, bone marrow, and lymphatic system. These cancers are often associated with specific genetic abnormalities, such as translocations. Here are some common translocations and their associated haematological malignancies:

– Philadelphia chromosome (t(9;22)): This translocation is present in more than 95% of patients with chronic myeloid leukaemia (CML). It results in the fusion of the Abelson proto-oncogene with the BCR gene on chromosome 22, creating the BCR-ABL gene. This gene codes for a fusion protein with excessive tyrosine kinase activity, which is a poor prognostic indicator in acute lymphoblastic leukaemia (ALL).

– t(15;17): This translocation is seen in acute promyelocytic leukaemia (M3) and involves the fusion of the PML and RAR-alpha genes.

– t(8;14): Burkitt’s lymphoma is associated with this translocation, which involves the translocation of the MYC oncogene to an immunoglobulin gene.

– t(11;14): Mantle cell lymphoma is associated with the deregulation of the cyclin D1 (BCL-1) gene.

– t(14;18): Follicular lymphoma is associated with increased BCL-2 transcription due to this translocation.

Understanding the genetic abnormalities associated with haematological malignancies is important for diagnosis, prognosis, and treatment.

Hydroxyurea is a medication that is used to treat various diseases, including sickle cell disease and chronic myelogenous leukaemia. It works by inhibiting ribonucleotide reductase, which reduces the production of deoxyribonucleotides. This, in turn, inhibits cell synthesis by decreasing DNA synthesis. It is important to note that hydroxyurea does not work by causing the cross-linking of DNA, which is a mechanism used by other drugs such as Cisplatin. Methotrexate works through the inhibition of dihydrofolate reductase, while Irinotecan inhibits topoisomerase I, and Cytarabine is a pyrimidine antagonist. These drugs work through different mechanisms and are not related to hydroxyurea.

Cytotoxic agents are drugs that are used to kill cancer cells. There are several types of cytotoxic agents, each with their own mechanism of action and potential adverse effects. Alkylating agents, such as cyclophosphamide, work by causing cross-linking in DNA. However, they can also cause haemorrhagic cystitis, myelosuppression, and transitional cell carcinoma. Cytotoxic antibiotics, like bleomycin and anthracyclines, degrade preformed DNA and stabilize DNA-topoisomerase II complex, respectively. However, they can also cause lung fibrosis and cardiomyopathy. Antimetabolites, such as methotrexate and fluorouracil, inhibit dihydrofolate reductase and thymidylate synthesis, respectively. However, they can also cause myelosuppression, mucositis, and liver or lung fibrosis. Drugs that act on microtubules, like vincristine and docetaxel, inhibit the formation of microtubules and prevent microtubule depolymerisation & disassembly, respectively. However, they can also cause peripheral neuropathy, myelosuppression, and paralytic ileus. Topoisomerase inhibitors, like irinotecan, inhibit topoisomerase I, which prevents relaxation of supercoiled DNA. However, they can also cause myelosuppression. Other cytotoxic drugs, such as cisplatin and hydroxyurea, cause cross-linking in DNA and inhibit ribonucleotide reductase, respectively. However, they can also cause ototoxicity, peripheral neuropathy, hypomagnesaemia, and myelosuppression.